Tumor Microenvironment Composition and Related Therapy in Hepatocellular Carcinoma

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN ESTIMATES OF INCIDENCE AND MORTALITY WORLDWIDE FOR 36 CANCERS IN 185 COUntries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Lin J, Zhang H, Yu H, et al. Epidemiological characteristics of primary liver cancer in Mainland China from 2003 to 2020: a Representative Multicenter Study. Front Oncol. 2022;12:906778. doi:10.3389/fonc.2022.906778
   PubMed Web of Science ®Google Scholar
• Jiang D, Zhang L, Liu W, et al. Trends in cancer mortality in China from 2004 to 2018: a nationwide longitudinal study. Cancer Commun. 2021;41(10):1024–1036. doi:10.1002/cac2.12195
   Web of Science ®Google Scholar
• Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345–1362. doi:10.1016/S0140-6736(22)01200-4
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. Systemic adjuvant treatment in hepatocellular carcinoma: tempted to do something rather than nothing. Future Oncol. 2020;16(32):2587–2589. doi:10.2217/fon-2020-0669
   PubMed Web of Science ®Google Scholar
• Lodetti Zangrandi G, Tirpanlar D, Pastore M, Soldani C, Lleo A, Raggi C. Tumor microenvironment highlighting tumor-associated macrophages and immune cells. Hepatoma Res. 2023;9:32. doi:10.20517/2394-5079.2023.32
   Google Scholar
• Boedtkjer E, Pedersen SF. The acidic tumor microenvironment as a driver of cancer. Annu Rev Physiol. 2020;82(1):103–126. doi:10.1146/annurev-physiol-021119-034627
   PubMed Web of Science ®Google Scholar
• Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 2019;18(1):60. doi:10.1186/s12943-019-0974-6
   PubMed Web of Science ®Google Scholar
• Wang SZ, Lee SD, Sarkar D, et al. Immunological characterization of hepatocellular carcinoma. Hepatoma Res. 2021;7:6.
   Google Scholar
• Sipos F, Műzes G. Cancer stem cell relationship with pro-tumoral inflammatory microenvironment. Biomedicines. 2023;11(1):189. doi:10.3390/biomedicines11010189
   PubMed Web of Science ®Google Scholar
• Liu W, Deng Y, Li Z, et al. Cancer evo-dev: a theory of inflammation-induced oncogenesis. Front Immunol. 2021;12:768098. doi:10.3389/fimmu.2021.768098
   PubMed Web of Science ®Google Scholar
• Huang A, Yang XR, Chung WY, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020;5(1):146. doi:10.1038/s41392-020-00264-x
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD. Challenges and future trends of hepatocellular carcinoma immunotherapy. Int J Mol Sci. 2022;23(19):11363. doi:10.3390/ijms231911363
   PubMed Web of Science ®Google Scholar
• Santoni M, Rizzo A, Kucharz J, et al. Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. Cancer Immunol Immunother. 2023;72(6):1365–1379. doi:10.1007/s00262-022-03349-4
   PubMed Web of Science ®Google Scholar
• Santoni M, Rizzo A, Mollica V, et al. The impact of gender on the efficacy of immune checkpoint inhibitors in cancer patients: the MOUSEION-01 study. Crit Rev Oncol Hematol. 2022;170:103596. doi:10.1016/j.critrevonc.2022.103596
   PubMed Web of Science ®Google Scholar
• Hinshaw D, Shevde L. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557–4566. doi:10.1158/0008-5472.CAN-18-3962
   PubMed Web of Science ®Google Scholar
• Jin H, Qin S, He J, et al. New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials. Int J Biol Sci. 2022;18(7):2775–2794. doi:10.7150/ijbs.70691
   PubMed Web of Science ®Google Scholar
• Murray PJ, Allen JE, Biswas SK, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41(1):14–20. doi:10.1016/j.immuni.2014.06.008
   PubMed Web of Science ®Google Scholar
• Zhou D, Luan J, Huang C, Li J. Tumor-associated macrophages in Hepatocellular carcinoma: friend or Foe? Gut Liver. 2021;15(4):500–516. doi:10.5009/gnl20223
   PubMed Web of Science ®Google Scholar
• Jiang Y, Han Q, Zhao H, Zhang J. Promotion of epithelial-mesenchymal transformation by hepatocellular carcinoma-educated macrophages through Wnt2b/β-catenin/c-Myc signaling and reprogramming glycolysis. J Exp Clin Cancer Res. 2021;40(1):13. doi:10.1186/s13046-020-01808-3
   PubMed Web of Science ®Google Scholar
• Wan S, Zhao E, Kryczek I, et al. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. Gastroenterology. 2014;147(6):1393–1404. doi:10.1053/j.gastro.2014.08.039
   PubMed Web of Science ®Google Scholar
• Yan W, Liu X, Ma H, et al. Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages. Gut. 2015;64(10):1593–1604. doi:10.1136/gutjnl-2014-307671
   PubMed Web of Science ®Google Scholar
• Song S, Yuan P, Li P, Wu H, Lu J, Wei W. Dynamic analysis of tumor-associated immune cells in DEN-induced rat hepatocellular carcinoma. Int Immunopharmacol. 2014;22(2):392–399. doi:10.1016/j.intimp.2014.07.007
   PubMed Web of Science ®Google Scholar
• Liu G, Yin L, Ouyang X, Zeng K, Xiao Y, Li Y. M2 macrophages promote HCC cells invasion and migration via miR-149-5p/MMP9 signaling. J Cancer. 2020;11(5):1277–1287. doi:10.7150/jca.35444
   PubMed Web of Science ®Google Scholar
• Li C, Jiang P, Wei S, Xu X, Wang J. Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects. Mol Cancer. 2020;19(1):116. doi:10.1186/s12943-020-01234-1
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang Q, Lou Y, et al. Hypoxia-inducible factor-1α/interleukin-1β signaling enhances hepatoma epithelial-mesenchymal transition through macrophages in a hypoxic-inflammatory microenvironment. Hepatology. 2018;67(5):1872–1889. doi:10.1002/hep.29681
   PubMed Web of Science ®Google Scholar
• Wang YF, Yuan SX, Jiang H, et al. Spatial maps of hepatocellular carcinoma transcriptomes reveal spatial expression patterns in tumor immune microenvironment. Theranostics. 2022;12(9):4163–4180. doi:10.7150/thno.71873
   PubMed Web of Science ®Google Scholar
• Dong P, Ma L, Liu L, et al. CD86⁺/CD206⁺, diametrically polarized tumor-associated macrophages, predict hepatocellular carcinoma patient prognosis. Int J Mol Sci. 2016;17(3):320. doi:10.3390/ijms17030320
   PubMed Web of Science ®Google Scholar
• Ning WR, Jiang D, Liu XC, et al. Carbonic anhydrase XII mediates the survival and prometastatic functions of macrophages in human hepatocellular carcinoma. J Clin Invest. 2022;132(7):e153110. doi:10.1172/JCI153110
   PubMed Web of Science ®Google Scholar
• Fridlender ZG, Sun J, Kim S, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2”. TAN Cancer Cell. 2009;16(3):183–194. doi:10.1016/j.ccr.2009.06.017
   PubMed Web of Science ®Google Scholar
• Arvanitakis K, Mitroulis I, Germanidis G. Tumor-associated neutrophils in Hepatocellular carcinoma pathogenesis, prognosis, and therapy. Cancers. 2021;13(12):2899. doi:10.3390/cancers13122899
   PubMed Web of Science ®Google Scholar
• Fridlender ZG, Albelda SM. Tumor-associated neutrophils: friend or foe? Carcinogenesis. 2012;33(5):949–955. doi:10.1093/carcin/bgs123
   PubMed Web of Science ®Google Scholar
• Zhou SL, Zhou ZJ, Hu ZQ, et al. Tumor-associated neutrophils recruit macrophages and T-regulatory cells to promote progression of Hepatocellular carcinoma and resistance to sorafenib. Gastroenterology. 2016;150(7):1646–58.e17. doi:10.1053/j.gastro.2016.02.040
   PubMed Web of Science ®Google Scholar
• Zhou SL, Yin D, Hu ZQ, et al. A positive feedback loop between cancer stem-like cells and tumor-associated neutrophils controls Hepatocellular carcinoma progression. Hepatology. 2019;70(4):1214–1230. doi:10.1002/hep.30630
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162–174. doi:10.1038/nri2506
   PubMed Web of Science ®Google Scholar
• Joshi S, Sharabi A. Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy. Pharmacol Ther. 2022;235:108114. doi:10.1016/j.pharmthera.2022.108114
   PubMed Web of Science ®Google Scholar
• Lu C, Rong D, Zhang B, et al. Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities. Mol Cancer. 2019;18(1):130. doi:10.1186/s12943-019-1047-6
   PubMed Web of Science ®Google Scholar
• Salmaninejad A, Valilou SF, Soltani A, et al. Tumor-associated macrophages: role in cancer development and therapeutic implications. Cell Oncol. 2019;42(5):591–608. doi:10.1007/s13402-019-00453-z
   PubMed Web of Science ®Google Scholar
• Yang R, Sun L, Li CF, et al. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat Commun. 2021;12(1):832. doi:10.1038/s41467-021-21099-2
   PubMed Web of Science ®Google Scholar
• Zhou J, Liu M, Sun H, et al. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy. Gut. 2018;67(5):931–944. doi:10.1136/gutjnl-2017-314032
   PubMed Web of Science ®Google Scholar
• Chiu DK, Tse AP, Xu IM, et al. Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma. Nat Commun. 2017;8(1):517. doi:10.1038/s41467-017-00530-7
   PubMed Web of Science ®Google Scholar
• Wang D, Li X, Li J, et al. APOBEC3B interaction with PRC2 modulates microenvironment to promote HCC progression. Gut. 2019;68(10):1846–1857. doi:10.1136/gutjnl-2018-317601
   PubMed Web of Science ®Google Scholar
• Xia S, Wu J, Zhou W, et al. SLC7A2 deficiency promotes hepatocellular carcinoma progression by enhancing recruitment of myeloid-derived suppressors cells. Cell Death Dis. 2021;12(6):570. doi:10.1038/s41419-021-03853-y
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wu T, Shao S, Shi B, Zhao Y. Phenotype, development, and biological function of myeloid-derived suppressor cells. Oncoimmunology. 2016;5(2):e1004983. doi:10.1080/2162402X.2015.1004983
   PubMed Web of Science ®Google Scholar
• Yin Z, Dong C, Jiang K, et al. Heterogeneity of cancer-associated fibroblasts and roles in the progression, prognosis, and therapy of hepatocellular carcinoma. J Hematol Oncol. 2019;12(1):101. doi:10.1186/s13045-019-0782-x
   PubMed Web of Science ®Google Scholar
• Mizutani Y, Kobayashi H, Iida T, et al. Meflin-positive cancer-associated fibroblasts inhibit pancreatic carcinogenesis. Cancer Res. 2019;79(20):5367–5381. doi:10.1158/0008-5472.CAN-19-0454
   PubMed Web of Science ®Google Scholar
• Lau EY, Lo J, Cheng BY, et al. Cancer-associated fibroblasts regulate tumor-initiating cell plasticity in Hepatocellular Carcinoma through c-Met/FRA1/HEY1 signaling. Cell Rep. 2016;15(6):1175–1189. doi:10.1016/j.celrep.2016.04.019
   PubMed Web of Science ®Google Scholar
• Li Y, Wang R, Xiong S, et al. Cancer-associated fibroblasts promote the stemness of CD24(+) liver cells via paracrine signaling. J Mol Med. 2019;97(2):243–255. doi:10.1007/s00109-018-1731-9
   PubMed Web of Science ®Google Scholar
• Xiong S, Wang R, Chen Q, et al. Cancer-associated fibroblasts promote stem cell-like properties of hepatocellular carcinoma cells through IL-6/STAT3/Notch signaling. Am J Cancer Res. 2018;8(2):302–316.
   PubMed Web of Science ®Google Scholar
• Fang T, Lv H, Lv G, et al. Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer. Nat Commun. 2018;9(1):191. doi:10.1038/s41467-017-02583-0
   PubMed Web of Science ®Google Scholar
• Zhou Y, Ren H, Dai B, et al. Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts. J Exp Clin Cancer Res. 2018;37(1):324. doi:10.1186/s13046-018-0965-2
   PubMed Web of Science ®Google Scholar
• Caligiuri A, Parola M, Marra F, Cannito S, Gentilini A. Cholangiocarcinoma tumor microenvironment highlighting fibrosis and matrix components. Hepatoma Res. 2023;9:30.
   Google Scholar
• She Q, Hu S, Pu X, Guo Q, Mou C, Yang C. The effect of hepatocellular carcinoma-associated fibroblasts on hepatoma vasculogenic mimicry. Am J Cancer Res. 2020;10(12):4198–4210.
   PubMed Web of Science ®Google Scholar
• Chen S, Morine Y, Tokuda K, et al. Cancer‑associated fibroblast‑induced M2‑polarized macrophages promote hepatocellular carcinoma progression via the plasminogen activator inhibitor‑1 pathway. Int J Oncol. 2021;59(2):59. doi:10.3892/ijo.2021.5239
   PubMed Web of Science ®Google Scholar
• Cheng JT, Deng YN, Yi HM, et al. Hepatic carcinoma-associated fibroblasts induce IDO-producing regulatory dendritic cells through IL-6-mediated STAT3 activation. Oncogenesis. 2016;5(2):e198. doi:10.1038/oncsis.2016.7
   PubMedGoogle Scholar
• Zhu GQ, Tang Z, Huang R, et al. CD36(+) cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor. Cell Discov. 2023;9(1):25. doi:10.1038/s41421-023-00529-z
   PubMed Web of Science ®Google Scholar
• Yang XH, Yamagiwa S, Ichida T, et al. Increase of CD4+ CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma. J Hepatol. 2006;45(2):254–262. doi:10.1016/j.jhep.2006.01.036
   PubMed Web of Science ®Google Scholar
• Cao M, Cabrera R, Xu Y, et al. Hepatocellular carcinoma cell supernatants increase expansion and function of CD4(+)CD25(+) regulatory T cells. Lab Invest. 2007;87(6):582–590. doi:10.1038/labinvest.3700540
   PubMed Web of Science ®Google Scholar
• Suthen S, Lim CJ, Nguyen PHD, et al. Hypoxia-driven immunosuppression by Treg and type-2 conventional dendritic cells in HCC. Hepatology. 2022;76(5):1329–1344. doi:10.1002/hep.32419
   PubMed Web of Science ®Google Scholar
• Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med. 1996;183(6):2533–2540. doi:10.1084/jem.183.6.2533
   PubMed Web of Science ®Google Scholar
• Jiang R, Tang J, Chen Y, et al. The long noncoding RNA lnc-EGFR stimulates T-regulatory cells differentiation thus promoting hepatocellular carcinoma immune evasion. Nat Commun. 2017;8:15129. doi:10.1038/ncomms15129
   PubMed Web of Science ®Google Scholar
• Lv D, Chen L, Du L, Zhou L, Tang H. Emerging regulatory mechanisms involved in liver cancer stem cell properties in Hepatocellular carcinoma. Front Cell Dev Biol. 2021;9:691410. doi:10.3389/fcell.2021.691410
   PubMedGoogle Scholar
• Lam KH, Ma S. Noncellular components in the liver cancer stem cell niche: biology and potential clinical implications. Hepatology. 2023;78(3):991–1005. doi:10.1002/hep.32629
   PubMed Web of Science ®Google Scholar
• Guo Y, Xiao Z, Yang L, et al. Hypoxia‑inducible factors in hepatocellular carcinoma (Review). Oncol Rep. 2020;43(1):3–15. doi:10.3892/or.2019.7397
   PubMed Web of Science ®Google Scholar
• Jing L, Ruan Z, Sun H, et al. Epithelial-mesenchymal transition induced cancer-stem-cell-like characteristics in hepatocellular carcinoma. J Cell Physiol. 2019;234(10):18448–18458. doi:10.1002/jcp.28480
   PubMed Web of Science ®Google Scholar
• Chen H, Nio K, Yamashita T, et al. BMP9-ID1 signaling promotes EpCAM-positive cancer stem cell properties in hepatocellular carcinoma. Mol Oncol. 2021;15(8):2203–2218. doi:10.1002/1878-0261.12963
   PubMed Web of Science ®Google Scholar
• Zhao X, Sun B, Liu T, et al. Long noncoding RNA n339260 promotes vasculogenic mimicry and cancer stem cell development in hepatocellular carcinoma. Cancer Sci. 2018;109(10):3197–3208. doi:10.1111/cas.13740
   PubMed Web of Science ®Google Scholar
• Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20(2):69–84. doi:10.1038/s41580-018-0080-4
   PubMed Web of Science ®Google Scholar
• Wei R, Zhu WW, Yu GY, et al. S100 calcium-binding protein A9 from tumor-associated macrophage enhances cancer stem cell-like properties of hepatocellular carcinoma. Int J Cancer. 2021;148(5):1233–1244. doi:10.1002/ijc.33371
   PubMed Web of Science ®Google Scholar
• Maniotis AJ, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. 1999;155(3):739–752. doi:10.1016/S0002-9440(10)65173-5
   PubMed Web of Science ®Google Scholar
• Zhao Z, Bai S, Wang R, et al. Cancer-associated fibroblasts endow stem-like qualities to liver cancer cells by modulating autophagy. Cancer Manag Res. 2019;11:5737–5744. doi:10.2147/CMAR.S197634
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Yoshio S, Yamazoe T, et al. Phenotypic characterization by single-cell mass cytometry of human intrahepatic and peripheral NK cells in patients with Hepatocellular carcinoma. Cells. 2021;10(6):1495. doi:10.3390/cells10061495
   PubMed Web of Science ®Google Scholar
• Mahgoub S, Abosalem H, Emara M, Kotb N, Maged A, Soror S. Restoring NK cells functionality via cytokine activation enhances cetuximab-mediated NK-cell ADCC: a promising therapeutic tool for HCC patients. Mol Immunol. 2021;137:221–227. doi:10.1016/j.molimm.2021.07.008
   PubMed Web of Science ®Google Scholar
• Cui C, Fu K, Yang L, et al. Hypoxia-inducible gene 2 promotes the immune escape of hepatocellular carcinoma from nature killer cells through the interleukin-10-STAT3 signaling pathway. J Exp Clin Cancer Res. 2019;38(1):229. doi:10.1186/s13046-019-1233-9
   PubMedGoogle Scholar
• Huang CF, Wang SC, Chang WT, et al. Lower protein expression levels of MHC class I chain-related gene A in hepatocellular carcinoma are at high risk of recurrence after surgical resection. Sci Rep. 2018;8(1):15821. doi:10.1038/s41598-018-34155-7
   PubMedGoogle Scholar
• Argenziano ME, Montori M, Scorzoni C, Benedetti A, Marzioni M, Maroni L. The role of tumor microenvironment in cholangiocarcinoma. Hepatoma Res. 2023;9:9. doi:10.20517/2394-5079.2022.98
   Google Scholar
• Zhang Q, He Y, Luo N, et al. Landscape and dynamics of single immune cells in Hepatocellular Carcinoma. Cell. 2019;179(4):829–45.e20. doi:10.1016/j.cell.2019.10.003
   PubMed Web of Science ®Google Scholar
• Deligne C, Midwood KS. Macrophages and extracellular matrix in breast cancer: partners in crime or protective allies? Front Oncol. 2021;11:620773. doi:10.3389/fonc.2021.620773
   PubMed Web of Science ®Google Scholar
• Tang H, You T, Sun Z, Bai C, Wang Y. Extracellular matrix-based gene expression signature defines two prognostic subtypes of Hepatocellular Carcinoma with different immune microenvironment characteristics. Front Mol Biosci. 2022;9:839806. doi:10.3389/fmolb.2022.839806
   PubMed Web of Science ®Google Scholar
• Winkler J, Abisoye-Ogunniyan A, Metcalf KJ, Werb Z. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat Commun. 2020;11(1):5120. doi:10.1038/s41467-020-18794-x
   PubMed Web of Science ®Google Scholar
• Cigliano A, Strain AJ, Cadamuro M. Signaling and molecular networks related to development and inflammation involved in CCA initiation and progression. Hepatoma Res. 2023;9(14):15. doi:10.20517/2394-5079.2023.09
   Google Scholar
• Li Z, Wang F, Li Y, et al. Combined anti-hepatocellular carcinoma therapy inhibit drug-resistance and metastasis via targeting “substance P-hepatic stellate cells-hepatocellular carcinoma” axis. Biomaterials. 2021;276:121003. doi:10.1016/j.biomaterials.2021.121003
   PubMed Web of Science ®Google Scholar
• Wang H, Rao B, Lou J, et al. The function of the HGF/c-met axis in Hepatocellular carcinoma. Front Cell Dev Biol. 2020;8:55. doi:10.3389/fcell.2020.00055
   PubMed Web of Science ®Google Scholar
• Ngo MT, Jeng HY, Kuo YC, et al. The role of IGF/IGF-1R signaling in Hepatocellular carcinomas: stemness-related properties and drug resistance. Int J Mol Sci. 2021;22(4):1931. doi:10.3390/ijms22041931
   PubMed Web of Science ®Google Scholar
• Gonzalez-Sanchez E, Vaquero J, Férnandez-Barrena MG, et al. The TGF-β pathway: a pharmacological target in Hepatocellular carcinoma? Cancers. 2021;13(13):3248. doi:10.3390/cancers13133248
   PubMed Web of Science ®Google Scholar
• Han L, Lin X, Yan Q, et al. PBLD inhibits angiogenesis via impeding VEGF/VEGFR2-mediated microenvironmental cross-talk between HCC cells and endothelial cells. Oncogene. 2022;41(13):1851–1865. doi:10.1038/s41388-022-02197-x
   PubMed Web of Science ®Google Scholar
• Xu J, Lin H, Wu G, Zhu M, Li M. IL-6/STAT3 is a promising therapeutic target for Hepatocellular carcinoma. Front Oncol. 2021;11:760971. doi:10.3389/fonc.2021.760971
   PubMed Web of Science ®Google Scholar
• Salman S, Meyers DJ, Wicks EE, et al. HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy. J Clin Invest. 2022;132(9):e156774. doi:10.1172/JCI156774
   PubMed Web of Science ®Google Scholar
• Cui Q, Wang X, Zhang Y, Shen Y, Qian Y. Macrophage-derived MMP-9 and MMP-2 are closely related to the rupture of the fibrous capsule of Hepatocellular carcinoma leading to tumor invasion. Biol Proced Online. 2023;25(1):8. doi:10.1186/s12575-023-00196-0
   PubMed Web of Science ®Google Scholar
• Cheung CCL, Seah YHJ, Fang J, et al. Immunohistochemical scoring of LAG-3 in conjunction with CD8 in the tumor microenvironment predicts response to immunotherapy in hepatocellular carcinoma. Front Immunol. 2023;14:1150985. doi:10.3389/fimmu.2023.1150985
   PubMed Web of Science ®Google Scholar
• Fernández-Palanca P, Payo-Serafín T, Méndez-Blanco C, et al. Neuropilins as potential biomarkers in hepatocellular carcinoma: a systematic review of basic and clinical implications. Clin Mol Hepatol. 2023;29(2):293–319. doi:10.3350/cmh.2022.0425
   PubMed Web of Science ®Google Scholar
• Zhao Y, Xu X, Wang Y, Wu LD, Luo RL, Xia RP. Tumor purity-associated genes influence hepatocellular carcinoma prognosis and tumor microenvironment. Front Oncol. 2023;13:1197898. doi:10.3389/fonc.2023.1197898
   PubMed Web of Science ®Google Scholar
• Zhou C, Sun BY, Zhou PY, et al. MAIT cells confer resistance to lenvatinib plus anti-PD1 antibodies in hepatocellular carcinoma through TNF-TNFRSF1B pathway [published online ahead of print, 2023 Sep 17]. Clin Immunol. 2023;256:109770. doi:10.1016/j.clim.2023.109770
   PubMed Web of Science ®Google Scholar
• Wang P, Cao J, Feng Z, et al. Oroxylin a promoted apoptotic extracellular vesicles transfer of glycolytic kinases to remodel immune microenvironment in hepatocellular carcinoma model. Eur J Pharmacol. 2023;957:176037. doi:10.1016/j.ejphar.2023.176037
   PubMed Web of Science ®Google Scholar
• Zhou G, Sprengers D, Boor PPC, et al. Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells in Hepatocellular Carcinomas. Gastroenterology. 2017;153(4):1107–19.e10. doi:10.1053/j.gastro.2017.06.017
   PubMed Web of Science ®Google Scholar
• Hilmi M, Neuzillet C, Calderaro J, Lafdil F, Pawlotsky JM, Rousseau B. Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions. J Immunother Cancer. 2019;7(1):333. doi:10.1186/s40425-019-0824-5
   PubMed Web of Science ®Google Scholar
• Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151–172. doi:10.1038/s41571-021-00573-2
   PubMed Web of Science ®Google Scholar
• Makarova-Rusher OV, Medina-Echeverz J, Duffy AG, Greten TF. The yin and yang of evasion and immune activation in HCC. J Hepatol. 2015;62(6):1420–1429. doi:10.1016/j.jhep.2015.02.038
   PubMed Web of Science ®Google Scholar
• Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018;18(3):168–182. doi:10.1038/nri.2017.131
   PubMed Web of Science ®Google Scholar
• Chan JD, Lai J, Slaney CY, Kallies A, Beavis PA, Darcy PK. Cellular networks controlling T cell persistence in adoptive cell therapy. Nat Rev Immunol. 2021;21(12):769–784. doi:10.1038/s41577-021-00539-6
   PubMed Web of Science ®Google Scholar
• Siracusano G, Tagliamonte M, Buonaguro L, Lopalco L. Cell surface proteins in Hepatocellular carcinoma: from bench to bedside. Vaccines. 2020;8(1):41. doi:10.3390/vaccines8010041
   Web of Science ®Google Scholar
• Dimri M, Satyanarayana A. Molecular signaling pathways and therapeutic targets in Hepatocellular carcinoma. Cancers. 2020;12(2):491. doi:10.3390/cancers12020491
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, Phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–2502. doi:10.1016/S0140-6736(17)31046-2
   PubMed Web of Science ®Google Scholar
• Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, Phase 3 trial. Lancet Oncol. 2022;23(1):77–90. doi:10.1016/S1470-2045(21)00604-5
   PubMed Web of Science ®Google Scholar
• Sangro B, Gomez-Martin C, de la Mata M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with Hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013;59(1):81–88. doi:10.1016/j.jhep.2013.02.022
   PubMed Web of Science ®Google Scholar
• Fang W, Yang Y, Ma Y, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 2018;19(10):1338–1350. doi:10.1016/S1470-2045(18)30495-9
   PubMed Web of Science ®Google Scholar
• Mo H, Huang J, Xu J, et al. Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study. Br J Cancer. 2018;119(5):538–545. doi:10.1038/s41416-018-0100-3
   PubMed Web of Science ®Google Scholar
• Lee DW, Cho EJ, Lee JH, et al. Phase II Study of avelumab in patients with advanced Hepatocellular carcinoma previously treated with sorafenib. Clin Cancer Res. 2021;27(3):713–718. doi:10.1158/1078-0432.CCR-20-3094
   PubMed Web of Science ®Google Scholar
• Ren Z, Ducreux M, Abou-Alfa GK, et al. Tislelizumab in patients with previously treated advanced Hepatocellular carcinoma (RATIONALE-208): a multicenter, non-randomized, open-label, phase 2 trial. Liver Cancer. 2022;12(1):72–84. doi:10.1159/000527175
   PubMed Web of Science ®Google Scholar
• Butterfield LH. Cancer vaccines. BMJ. 2015;350:h988.
   PubMed Web of Science ®Google Scholar
• Han CL, Yan YC, Yan LJ, et al. Efficacy and security of tumor vaccines for hepatocellular carcinoma: a systemic review and meta-analysis of the last 2 decades. J Cancer Res Clin Oncol. 2023;149(4):1425–1441. doi:10.1007/s00432-022-04008-y
   PubMed Web of Science ®Google Scholar
• Cai Z, Su X, Qiu L, et al. Personalized neoantigen vaccine prevents postoperative recurrence in Hepatocellular carcinoma patients with vascular invasion. Mol Cancer. 2021;20(1):164. doi:10.1186/s12943-021-01467-8
   PubMed Web of Science ®Google Scholar
• Wang WC, Zhang ZQ, Li PP, et al. Anti-tumor activity and mechanism of oligoclonal hepatocellular carcinoma tumor-infiltrating lymphocytes in vivo and in vitro. Cancer Biol Ther. 2019;20(9):1187–1194. doi:10.1080/15384047.2019.1599663
   PubMed Web of Science ®Google Scholar
• Yu SJ, Ma C, Heinrich B, et al. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in Hepatocellular carcinoma. J Hepatol. 2019;70(3):449–457. doi:10.1016/j.jhep.2018.10.040
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zhang Z, Peng M, Fu S, Xue Z, Zhang R. CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: from bench to bedside. Oncoimmunology. 2016;5(12):e1251539. doi:10.1080/2162402X.2016.1251539
   PubMed Web of Science ®Google Scholar
• Chen L, Qiao D, Wang J, Tian G, Wang M. Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers. Immunol Lett. 2019;216:51–62. doi:10.1016/j.imlet.2019.10.002
   PubMed Web of Science ®Google Scholar
• Pang N, Shi J, Qin L, et al. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin. J Hematol Oncol. 2021;14(1):118. doi:10.1186/s13045-021-01128-9
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen M, Wu Z, et al. CD133-directed CAR T cells for advanced metastasis malignancies: a Phase I trial. Oncoimmunology. 2018;7(7):e1440169. doi:10.1080/2162402X.2018.1440169
   PubMed Web of Science ®Google Scholar
• Spear TT, Callender GG, Roszkowski JJ, et al. TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors. Cancer Immunol Immunother. 2016;65(3):293–304. doi:10.1007/s00262-016-1800-2
   PubMed Web of Science ®Google Scholar
• Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7):917–924. doi:10.1200/JCO.2010.32.2537
   PubMed Web of Science ®Google Scholar
• Luo X, Cui H, Cai L, et al. Selection of a clinical lead TCR targeting alpha-fetoprotein-positive liver cancer based on a balance of risk and benefit. Front Immunol. 2020;11:623. doi:10.3389/fimmu.2020.00623
   PubMed Web of Science ®Google Scholar
• Ramadori G. C-kit expression in cancer cells or hematopoietic cells of the tumoral microenvironment: which is the basis for efficacy of TK inhibitors and immunotherapy in HCC? Hepatoma Res. 2021;7:69.
   Google Scholar
• Feng ZY, Xu FG, Liu Y, et al. The immune microenvironment and progression of immunotherapy and combination therapeutic strategies for hepatocellular carcinoma. Hepatoma Res. 2021;7:3.
   Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. doi:10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi:10.1016/S0140-6736(18)30207-1
   PubMed Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66. doi:10.1016/S0140-6736(16)32453-9
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing Hepatocellular carcinoma. N Engl J Med. 2018;379(1):54–63. doi:10.1056/NEJMoa1717002
   PubMed Web of Science ®Google Scholar
• Kudo M, Hatano E, Ohkawa S, et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial. J Gastroenterol. 2017;52(4):494–503. doi:10.1007/s00535-016-1247-4
   PubMed Web of Science ®Google Scholar
• Qin S, Li Q, Gu S, et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2021;6(7):559–568. doi:10.1016/S2468-1253(21)00109-6
   PubMed Web of Science ®Google Scholar
• Bouattour M, Raymond E, Qin S, et al. Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma. Hepatology. 2018;67(3):1132–1149. doi:10.1002/hep.29496
   PubMed Web of Science ®Google Scholar
• Kim RD, Sarker D, Meyer T, et al. First-in-human Phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in Hepatocellular carcinoma. Cancer Discov. 2019;9(12):1696–1707. doi:10.1158/2159-8290.CD-19-0555
   PubMed Web of Science ®Google Scholar
• Faivre S, Santoro A, Kelley RK, et al. Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma. Liver Int. 2019;39(8):1468–1477. doi:10.1111/liv.14113
   PubMed Web of Science ®Google Scholar
• Murali M, Kumar AR, Nair B, et al. Antibody-drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance. Clin Transl Oncol. 2022;24(3):407–431. doi:10.1007/s12094-021-02707-5
   PubMed Web of Science ®Google Scholar
• Kong FE, Li GM, Tang YQ, et al. Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate. Sci Transl Med. 2021;13(579):eabb6282. doi:10.1126/scitranslmed.abb6282
   PubMed Web of Science ®Google Scholar
• Yang CY, Wang L, Sun X, et al. SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models. Acta Pharmacol Sin. 2019;40(7):971–979. doi:10.1038/s41401-018-0198-0
   PubMed Web of Science ®Google Scholar
• Ma Y, Zhang M, Wang J, et al. High-affinity human anti-c-Met IgG conjugated to oxaliplatin as targeted chemotherapy for Hepatocellular carcinoma. Front Oncol. 2019;9:717. doi:10.3389/fonc.2019.00717
   PubMed Web of Science ®Google Scholar
• Hoseini SS, Cheung NV. Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies. Cancer Lett. 2017;399:44–52. doi:10.1016/j.canlet.2017.04.013
   PubMed Web of Science ®Google Scholar
• Du K, Li Y, Liu J, et al. A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC. Mol Ther. 2021;29(4):1572–1584. doi:10.1016/j.ymthe.2021.01.006
   PubMed Web of Science ®Google Scholar
• Yu L, Huang N, Sun H, et al. Development of a tetravalent T-cell engaging bispecific antibody against glypican-3 for Hepatocellular carcinoma. J Immunother. 2021;44(3):106–113. doi:10.1097/CJI.0000000000000349
   PubMed Web of Science ®Google Scholar
• Liao Y, Tang Z, Liu K, et al. Preparation and application of anti-HBx/anti-CD3 bispecific monoclonal antibody (BsAb) retargeting effector cells for lysis of human hepatoma xenografts in nude mice. Oncol Rep. 1996;3(4):637–644.
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Finn RS, Ikeda M, Zhu AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable Hepatocellular Carcinoma. J Clin Oncol. 2020;38(26):2960–2970. doi:10.1200/JCO.20.00808
   PubMed Web of Science ®Google Scholar
• Xia Y, Tang W, Qian X, et al. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial. J Immunother Cancer. 2022;10(4):e004656. doi:10.1136/jitc-2022-004656
   PubMed Web of Science ®Google Scholar
• Kelley RK, Rimassa L, Cheng AL, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(8):995–1008. doi:10.1016/S1470-2045(22)00326-6
   PubMed Web of Science ®Google Scholar
• Cousin S, Cantarel C, Guegan JP, et al. Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial. Eur J Cancer. 2022;162:161–169. doi:10.1016/j.ejca.2021.11.012
   PubMed Web of Science ®Google Scholar
• Ho WJ, Zhu Q, Durham J, et al. Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity. Nat Cancer. 2021;2(9):891–903. doi:10.1038/s43018-021-00234-4
   PubMedGoogle Scholar
• Kaseb AO, Morris JS, Iwasaki M, et al. Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma. Onco Targets Ther. 2016;9:773–780. doi:10.2147/OTT.S91977
   PubMed Web of Science ®Google Scholar
• Mahmood S, Li D, Lee A, et al. A multicenter, phase Ib/II, open-label study of tivozanib with durvalumab in advanced hepatocellular carcinoma (DEDUCTIVE). Future Oncol. 2022;18(40):4465–4471. doi:10.2217/fon-2022-0844
   PubMed Web of Science ®Google Scholar
• Qin S, Chen M, Cheng AL, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;S0140-6736(23):01796–01798.
   Google Scholar
• Song X, Kelley RK, Khan AA, et al. Exposure-response analyses of tremelimumab monotherapy or in combination with durvalumab in patients with unresectable Hepatocellular carcinoma. Clin Cancer Res. 2023;29(4):754–763. doi:10.1158/1078-0432.CCR-22-1983
   PubMed Web of Science ®Google Scholar
• Settleman J, Neto JMF, Bernards R. Thinking differently about cancer treatment regimens. Cancer Discov. 2021;11(5):1016–1023. doi:10.1158/2159-8290.CD-20-1187
   PubMed Web of Science ®Google Scholar
• Ningarhari M, Caruso S, Hirsch TZ, et al. Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target [published correction appears in J Hepatol. 2022 May;76(5):1242–1243]. J Hepatol. 2021;74(5):1155–1166. doi:10.1016/j.jhep.2020.11.052
   PubMed Web of Science ®Google Scholar
• Yu F, Yu C, Li F, et al. Wnt/β-catenin signaling in cancers and targeted therapies. Signal Transduct Target Ther. 2021;6(1):307. doi:10.1038/s41392-021-00701-5
   PubMed Web of Science ®Google Scholar
• Chen S, Wu JL, Liang Y, et al. Arsenic trioxide rescues structural p53 mutations through a cryptic allosteric site. Cancer Cell. 2021;39(2):225–239.e8. doi:10.1016/j.ccell.2020.11.013
   PubMed Web of Science ®Google Scholar
• McGrail DJ, Pilié PG, Rashid NU, et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021;32(5):661–672. doi:10.1016/j.annonc.2021.02.006
   PubMed Web of Science ®Google Scholar
• Winograd P, Hou S, Court CM, et al. Hepatocellular carcinoma-circulating tumor cells expressing PD-L1 are prognostic and potentially associated with response to checkpoint inhibitors. Hepatol Commun. 2020;4(10):1527–1540. doi:10.1002/hep4.1577
   PubMed Web of Science ®Google Scholar
• Kim AK, Hamilton JP, Lin SY, et al. Urine DNA biomarkers for hepatocellular carcinoma screening. Br J Cancer. 2022;126(10):1432–1438. doi:10.1038/s41416-022-01706-9
   PubMed Web of Science ®Google Scholar